Research into the effective treatments for gastrointestinal cancers (GICs) has gained momentum with the discovery of CLDN18.2. This protein shows limited expression in healthy tissues but exhibits abnormal expression in various digestive malignancies. In this article, Heemali Kamdar, DO, a GI Fellow at Nemours Children’s Hospital in Wilmington, Delaware, discusses the latest advancements in CLDN18.2 targeted therapy for the management of GICs.
Special Collections
Clinician POV
Karen Louw, NP, discusses high-risk markers for MM, the emergence of GPRC5D-targeted and BCMA-targeted CAR T-cell therapies, and efficacy data for emerging CAR T-cell therapies for the management of MM.
Kristi A. Acker, DNP, PhD, FNP-BC, AOCNP, ACHPN, of the University of Alabama, Tuscaloosa, discusses maintenance therapy strategies for recurrent ovarian cancer.
Srinivas S. Devarakonda, MD, assistant professor in the division of hematology at James Cancer Hospital and Solove Research Institute of The Ohio State University Wexner Medical Center, Columbus, Ohio, discusses therapies targeting CD38 for patients with multiple myeloma.
Charles Shapiro, MD, medical oncologist and director of Translational Breast Cancer Research for the Mount Sinai Health System, in New York, discusses promising research and therapeutic strategies for patients with high-risk, HER2-positive early breast cancer.
